FDA APPROVES CUBICIN

Article

The FDA has approved Cubicin, a product of Cubist Pharmaceuticals that was formally called Cidecin, for treatment of complicated skin and structure infections caused by gram-positive bacteria.

Related Videos
Related Content

Verrica Supports FDA Warning of Unapproved Products to Treat Molluscum Contagiosum

August 23rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Promoting Beneficial Skin Care and Self Care Habits Among Teenagers

August 9th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023

Single-Strain Probiotic Has Positive Effect on Atopic Dermatitis in Pediatric Patients

July 20th 2023

Verrica Supports FDA Warning of Unapproved Products to Treat Molluscum Contagiosum

August 23rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Promoting Beneficial Skin Care and Self Care Habits Among Teenagers

August 9th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023

Single-Strain Probiotic Has Positive Effect on Atopic Dermatitis in Pediatric Patients

July 20th 2023

Verrica Supports FDA Warning of Unapproved Products to Treat Molluscum Contagiosum

August 23rd 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

Promoting Beneficial Skin Care and Self Care Habits Among Teenagers

August 9th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

VP-102 Now Approved for the Treatment of Molluscum Contagiosum

July 21st 2023

Single-Strain Probiotic Has Positive Effect on Atopic Dermatitis in Pediatric Patients

July 20th 2023
© 2023 MJH Life Sciences

All rights reserved.